Study Title:
A Phase III Study of Daunorubicin and Cytarabine +\- G3139 (GenasenseTM; Oblimersen Sodium; NSC #683428; IND #58842); A BCL2 Antisense Oligodeoxynucleotide; in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > 60 Years
Lead Group:
Status:
Review Status: